Investigating new treatments for cocaine and opioid addiction
Non-beta-lactam GLT-1 activators: characterization in preclinical models of opioid and cocaine addiction
This study is looking at new medications to help people struggling with cocaine and opioid addiction by focusing on a brain protein that helps control a key chemical, aiming to find safer and more effective treatments that could reduce cravings and prevent relapse.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Temple Univ of the Commonwealth NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10873925 on NIH RePORTER |
What this research studies
This research focuses on developing new medications for cocaine and opioid addiction by targeting the glutamate transporter subtype 1 (GLT-1), which plays a crucial role in regulating glutamate levels in the brain. The study aims to evaluate the effectiveness of non-beta-lactam GLT-1 activators in preclinical models, addressing the limitations of current treatments that often have abuse potential. By enhancing GLT-1 function, the research seeks to reduce drug dependence and relapse rates. Patients may benefit from potential new therapies that are safer and more effective than existing options.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with a history of cocaine or opioid addiction who are seeking new treatment options.
Not a fit: Patients who are not struggling with substance use disorders may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new, effective treatments for individuals struggling with cocaine and opioid addiction.
How similar studies have performed: Previous research has shown promise in targeting the glutamate system for addiction treatment, but this approach with non-beta-lactam activators is relatively novel.
Where this research is happening
Philadelphia, United States
- Temple Univ of the Commonwealth — Philadelphia, United States (Active)
Researchers
- Principal investigator: Rawls, Scott M. — Temple Univ of the Commonwealth
- Study coordinator: Rawls, Scott M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.